Literature DB >> 35902432

Escalating de-escalation in breast cancer treatment.

Virgilio Sacchini1, Larry Norton2.   

Abstract

Efforts have continually been made to de-escalate treatment for breast cancer, with the goal of balancing oncologic outcomes with complications and patient quality of life. In the early 2000s, two landmark studies firmly established that conservative treatment approaches for breast cancer can be safe and effective. More recently, neoadjuvant chemotherapy has gained momentum as a potential standard of care for breast cancer. An important question has thus arisen: Can neoadjuvant approaches themselves be de-escalated to further minimize adverse treatment effects while maintaining oncological outcomes? In this editorial, we look at the available evidence and assess current trends in treatment de-escalation for women with breast cancer.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Breast cancer; Multimodality therapy; Neoadjuvant chemotherapy; Preoperative MRI; Surgical de-escalation; Upfront surgery

Mesh:

Year:  2022        PMID: 35902432     DOI: 10.1007/s10549-022-06685-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.624


  39 in total

1.  COMPLICATIONS IN POSTOPERATIVE IRRADIATION OF MAMMARY CARCINOMA. OBSERVATIONS IN 585 PATIENTS TREATED AT RADIUMHEMMET 1955--1960.

Authors:  F EDSMYR; R WALSTAM
Journal:  Acta Radiol Ther Phys Biol       Date:  1963-12

2.  The Halsted mastectomy: present illness and past history.

Authors:  C S Bland
Journal:  West J Med       Date:  1981-06

3.  Combination chemotherapy as an adjuvant treatment in operable breast cancer.

Authors:  G Bonadonna; E Brusamolino; P Valagussa; A Rossi; L Brugnatelli; C Brambilla; M De Lena; G Tancini; E Bajetta; R Musumeci; U Veronesi
Journal:  N Engl J Med       Date:  1976-02-19       Impact factor: 91.245

4.  Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

Authors:  Joanne L Blum; Patrick J Flynn; Greg Yothers; Lina Asmar; Charles E Geyer; Samuel A Jacobs; Nicholas J Robert; Judith O Hopkins; Joyce A O'Shaughnessy; Chau T Dang; Henry Leonidas Gómez; Louis Fehrenbacher; Svetislava J Vukelja; Alan P Lyss; Devchand Paul; Adam M Brufsky; Jong-Hyeon Jeong; Linda H Colangelo; Sandra M Swain; Eleftherios P Mamounas; Stephen E Jones; Norman Wolmark
Journal:  J Clin Oncol       Date:  2017-04-11       Impact factor: 44.544

5.  Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.

Authors:  N Harbeck; P Rastogi; M Martin; S M Tolaney; Z M Shao; P A Fasching; C S Huang; G G Jaliffe; A Tryakin; M P Goetz; H S Rugo; E Senkus; L Testa; M Andersson; K Tamura; L Del Mastro; G G Steger; H Kreipe; R Hegg; J Sohn; V Guarneri; J Cortés; E Hamilton; V André; R Wei; S Barriga; S Sherwood; T Forrester; M Munoz; A Shahir; B San Antonio; S C Nabinger; M Toi; S R D Johnston; J O'Shaughnessy
Journal:  Ann Oncol       Date:  2021-10-14       Impact factor: 32.976

6.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

Authors:  Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

7.  Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.

Authors:  Umberto Veronesi; Natale Cascinelli; Luigi Mariani; Marco Greco; Roberto Saccozzi; Alberto Luini; Marisel Aguilar; Ettore Marubini
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

8.  Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

Authors:  Luca Gianni; José Baselga; Wolfgang Eiermann; Vincente Guillem Porta; Vladimir Semiglazov; Ana Lluch; Milvia Zambetti; Dolores Sabadell; Günther Raab; Antonio Llombart Cussac; Alla Bozhok; Angel Martinez-Agulló; Marco Greco; Mikhail Byakhov; Juan Josè Lopez Lopez; Mauro Mansutti; Pinuccia Valagussa; Gianni Bonadonna
Journal:  J Clin Oncol       Date:  2009-03-30       Impact factor: 44.544

9.  Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

Authors:  Andrew N J Tutt; Judy E Garber; Bella Kaufman; Giuseppe Viale; Debora Fumagalli; Priya Rastogi; Richard D Gelber; Evandro de Azambuja; Anitra Fielding; Judith Balmaña; Susan M Domchek; Karen A Gelmon; Simon J Hollingsworth; Larissa A Korde; Barbro Linderholm; Hanna Bandos; Elżbieta Senkus; Jennifer M Suga; Zhimin Shao; Andrew W Pippas; Zbigniew Nowecki; Tomasz Huzarski; Patricia A Ganz; Peter C Lucas; Nigel Baker; Sibylle Loibl; Robin McConnell; Martine Piccart; Rita Schmutzler; Guenther G Steger; Joseph P Costantino; Amal Arahmani; Norman Wolmark; Eleanor McFadden; Vassiliki Karantza; Sunil R Lakhani; Greg Yothers; Christine Campbell; Charles E Geyer
Journal:  N Engl J Med       Date:  2021-06-03       Impact factor: 176.079

10.  Pembrolizumab for Early Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Javier Cortes; Lajos Pusztai; Heather McArthur; Sherko Kümmel; Jonas Bergh; Carsten Denkert; Yeon Hee Park; Rina Hui; Nadia Harbeck; Masato Takahashi; Theodoros Foukakis; Peter A Fasching; Fatima Cardoso; Michael Untch; Liyi Jia; Vassiliki Karantza; Jing Zhao; Gursel Aktan; Rebecca Dent; Joyce O'Shaughnessy
Journal:  N Engl J Med       Date:  2020-02-27       Impact factor: 176.079

View more
  2 in total

1.  Screening MRI in Patients with High-Risk Breast Lesions: More May Not Necessarily be More.

Authors:  Juan C Paramo; Roshni Rao
Journal:  Ann Surg Oncol       Date:  2022-09-25       Impact factor: 4.339

2.  Survival of women with pregnancy-associated breast cancer according to clinical characteristics: A propensity score matching study.

Authors:  Hongki Gwak; Sang Seok Woo; Eun-Sook Lee; Min Ho Park; Seokwon Lee; Hyun Jo Youn; Seho Park; In Suck Suh; Seong Hwan Kim
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.